参考文献:1.Siegel R et al (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9鈥?9CrossRef PubMed 2.Jarosek SL et al (2015) Propensity-weighted long-term risk of urinary adverse events after prostate cancer surgery, radiation, or both. Eur Urol 67(2):273鈥?80CrossRef PubMed 3.Warren JL et al (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(8Suppl):IV-3鈥揑V-18 4.Penson DF et al (2001) Determining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst 93(23):1822鈥?823CrossRef PubMed 5.Albertsen PC, Walters S, Hanley JA (2000) A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995. J Urol 163(2):519鈥?23CrossRef PubMed 6.Klabunde CN et al (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53(12):1258鈥?267CrossRef PubMed 7.Sun M et al (2011) Racial disparities and socioeconomic status in men diagnosed with testicular germ cell tumors: a survival analysis. Cancer 117(18):4277鈥?285CrossRef PubMed 8.Droz JP et al (2014) Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 15(9):e404鈥揺414CrossRef PubMed 9.Austenfeld MS, Thompson IM Jr, Middleton RG (1994) Meta-analysis of the literature: guideline development for prostate cancer treatment. American Urological Association Prostate Cancer Guideline Panel. J Urol 152(5 Pt 2):1866鈥?869PubMed 10.Thompson I et al (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177(6):2106鈥?131CrossRef PubMed
作者单位:Roger Valdivieso (1) (2) Katharina Boehm (1) (3) Malek Meskawi (1) (2) Alessandro Larcher (1) (4) Zhe Tian (1) Marie-Elise Parent (5) (6) Philip Wong (7) Markus Graefen (3) Francesco Montorsi (4) Maxine Sun (1) Fred Saad (2) Pierre I. Karakiewicz (1) (2)
1. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, 264 Blvd. Rene-Levesque E. Room 228, Montreal, QC, H2X 1P1, Canada 2. Department of Urology, University of Montreal Health Center, Montreal, QC, Canada 3. Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany 4. Division of Oncology, Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy 5. INRS-Institut Armand-Frappier, Institut National de la Recherche Scientifique, Laval, QC, Canada 6. University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada 7. Department of Radiation Oncology, University of Montreal Health Center, Montreal, QC, Canada
刊物类别:Medicine
刊物主题:Medicine & Public Health Urology and Andrology Nephrology Oncology
出版者:Springer Berlin / Heidelberg
ISSN:1433-8726
文摘
Background Brachytherapy (BT) is a widely used treatment modality for elderly patients with localized prostate cancer (PCa).